Opendata, web and dolomites

ENDOCAM SIGNED

TARGETING ENDOTHELIAL CELL AND CANCER AMOEBOID MOVEMENT TO OVERCOME RESISTANCE TO ANTI-VEGF AND ANTI-PROTEASE THERAPIES

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ENDOCAM project word cloud

Explore the words cloud of the ENDOCAM project. It provides you a very rough idea of what is the project "ENDOCAM" about.

physiologic    invasion    shared    strategy    mature    hypothesized    ephrin    epcs    clinical    barriers    serine    therapeutic    showed    ascribed    metallo    outcomes    molecules    onset    treatment    protease    mechanisms    amoeboid    vegfa    disease    overcoming    attack    movement    synthetic    actin    tumors    mimicking    cytoskeleton    glide    endothelial    movements    migration    stimulation    ecs    mpis    candidates    humans    strategies    opportunistic    adaptations    cysteine    cell    proteases    experiments    environment    angiogenesis    anti    ecm    progress    cells    multiple    physiological    vessel    motility    vascular    degrade    give    regulation    progression    skip    patients    progenitor    preliminary    impairing    differences    connection    unlike    mpi    metalloproteinase    mixture    disregarded    indifference    therapy    liposomes    cortical    receptors    blood    resistance    time    followed    existence    cargo    containing    inhibitors    body    expectations    perspective    mesenchymal    cancer    vegf   

Project "ENDOCAM" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITA DEGLI STUDI DI FIRENZE 

Organization address
address: Piazza San Marco 4
city: Florence
postcode: 50121
website: http://www.unifi.it

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website http://www.unifi.it
 Total cost 244˙269 €
 EC max contribution 244˙269 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2016
 Funding Scheme MSCA-IF-GF
 Starting year 2017
 Duration (year-month-day) from 2017-12-01   to  2020-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITA DEGLI STUDI DI FIRENZE IT (Florence) coordinator 244˙269.00
2    THE REGENTS OF THE UNIVERSITY OF CALIFORNIA US (OAKLAND CA) partner 0.00

Map

 Project objective

Unlike mesenchymal migration, the amoeboid motility doesn’t require proteases and is an opportunistic movement of cancer cells which allows cells to glide through, rather than degrade, ECM barriers, using movements based on adaptations of the cell body. Preliminary experiments we conducted using a mixture of physiologic inhibitors of serine-proteases, metallo-proteases and cysteine-proteases, thus mimicking a physiological environment, showed no differences in vessel formation for both Endothelial Progenitor Cells (EPCs) and mature Endothelial Cells (ECs) under mesenchymal or amoeboid conditions. Thus, we hypothesized the existence of an “amoeboid angiogenesis”. We also hypothesized that the failure of cancer treatment using synthetic metalloproteinase inhibitors (MPIs) could be ascribed to the ability of cancer and ECs to skip the attack of the MPI therapy by allowing cancer invasion and blood vessel formation using the “amoeboid” strategy. Even the VEGFA targeting partially disregarded the expectations because of the resistance onset followed by the progression of the disease. Our preliminary experiments showed also an “indifference” of ECs and EPCs to VEGF stimulation under amoeboid conditions. Therefore, the aim of this project is to identify the multiple mechanisms shared by cancer cells and ECs/EPCs in the regulation of amoeboid movement, to identify common therapeutic strategies impairing vascular growth and cancer cell invasion at the same time, overcoming resistance to anti-VEGF and anti-protease therapy. The molecules identified (ephrin, protease receptors, etc.) will be used as candidates for targeted therapy through the delivery of cargo liposomes containing inhibitors of the connection of such molecules with the cortical actin cytoskeleton, in pre-clinical experiments with the perspective of a possible application to humans. We expect that this approach will give a progress in the treatment of tumors thus improving outcomes for cancer patients.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ENDOCAM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ENDOCAM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

Photonic Radar (2019)

Implementation of Long Reach Hybrid Photonic Radar System and convergence over FSO and PON Networks

Read More  

CLIMACY (2020)

Practices of Climate Diplomacy and Uneven Policy Responses on Climate Change on Human Mobility

Read More  

LICONAMCO (2019)

Light-controlled nanomagnetic computation schemes

Read More